AMR
ARLINGTON MEDICAL RESOURCES
A Decision Resources Group Company

REPORT SERIES OVERVIEW

HOSPITAL FORMULARY INSIGHTS – ANTI-INFECTIVES

This study will provide an in-depth view of the hospital formulary decision-making process for antibiotics and antifungal therapies. Through primary market research with hospital pharmacy directors and infectious disease specialists that sit on their hospital's P&T committee, we are able to understand the influence of cost factors, clinical factors, and product attributes on anti-infective formulary decisions. In addition, *Hospital Formulary Insights* provides information on the formulary and restriction status of key antibiotic and antifungal brands and why drugs are or are not included on hospital formulary.

SAMPLE FRAME & METHODOLOGY

30-40 minute online survey

Hospital pharmacy directors that sit on their hospital's P&T committee

ID specialists that sit on their hospital's P&T committee and have at least 55% of their practice in the hospital setting.

FIELDING AND PUBLICATION SCHEDULE

Field October 2011
Publish November 2011

PROJECT OBJECTIVES

- P&T committee overview – structure, frequency of meetings, subcommittees, members with voting rights, key influencers on formulary decisions, and topical issues discussed, use of anti-infective subcommittees
- Understand factors that influence formulary decision-making including drug specific attributes, pharmacoeconomic data, and how physicians and pharmacists incorporate cost and the assessment of a drug's value into their formulary decisions
- Understand factors that influence physician access to formulary and non-formulary including antimicrobial stewardship programs, therapeutic interchange policies, drug-specific restrictions, and drug stocking
- Identify clinical and administrative challenges for formulary approval of new products
- Understand the process of formulary placement/inclusion of new therapies including formulary moratoriums or trial usage of new drugs
- Assess formulary status, detailed restrictions, and hospital stocking of all currently marketed antibacterial and antifungal brands
- Detailed assessment of the formulary decision making process for recently launched brands including TEFLARO, DIFICID, and VIBATIV and P&T committees view of these products relative to the competition
- Evaluate the influence of P&T committees on drug use at discharge

RELATED REPORTS

Hospital Antibiotic Market Guide: patient-level audit of antibiotic use in the hospital including drug usage analysis by treatment intent, line of therapy, diagnosis, prescribing physicians, number of drug-treated patients, days of therapy.

Hospital Antifungal Market Guide: patient-level audit of antifungal use in the hospital including drug usage analysis by treatment intent, line of therapy, diagnosis, prescribing physicians, number of drug-treated patients, days of therapy.

LaunchTrends® Institutional - Teflaro: series of three post-launch reports that evaluate the trial and usage of Teflaro for the treatment of bacterial infections, including cSSSIs and CABP, through one-year post-launch.

LaunchTrends® Institutional - Dificid: This 4-report series includes one pre-launch report and three post-launch reports that evaluate the trial and usage of Dificid by ID specialists and internists(including those with nursing home/long-term care facility practice) for the treatment of *Clostridium difficile* infection.

LaunchTrends® Institutional is a syndicated report series that tracks the trial, adoption, and usage of new products from pre-launch through one year post-launch. These reports provide information on how new products fit into the treatment algorithm, impact current therapies, and change market dynamics. They provide information on awareness, familiarity, and perceived clinical advantages and disadvantages of new products. Moreover, they capture the promotional messages and activities of all market players.

For more information, or the full report contact Todd Samuelson (U.S.) at tsamuelson@amr-data.com or Inge Cornelis (Europe) at icornelis@amr-data.com